Molecular Imaging: Page 20

CMS lifts limit on amyloid PET coverage

CMS has lifted its coverage limit of one amyloid PET scan per lifetime for patients with Alzheimer’s disease.

October 13, 2023

TRIGA reactor fuel supply restored in the U.S

Pennsylvania State University has received the first TRIGA nuclear research reactor fuel delivery in the U.S. in a decade.

October 12, 2023

Penn State received the TRIGA reactor fuel on September 27.

PET study questions equity of NFL’s concussion settlement

PET brain scans of former NFL players with dementia due to repetitive head impacts do not show typical signs of Alzheimer’s disease.

October 10, 2023

Amyloid PET scans improve outcomes in AD patients

Alzheimer’s disease (AD) patients with cognitive impairment or dementia who were referred for amyloid PET scans had fewer hospitalizations compared with a matched control group.

October 9, 2023

Does a dedicated PET prostate cancer scanner have clinical potential?

A recently built small PET scanner may improve the detection of prostate cancer and could ultimately reduce invasive patient biopsies to confirm disease.

October 6, 2023

A photograph of the detector ring of the ProsPET system.

SNMMI highlights PET study in breast cancer patients

A PET/CT study in women with breast cancer features a radiotracer that could replace invasive biopsies for detecting metastatic disease.

October 2, 2023

Ga-68 ABY-025 PET/CT and F-18 FDG-PET/CT images at baseline with F-18 FDG PET/CT follow-up after two cycles of treatment in biopsy-confirmed HER2-positive disease. (A) Patient with high Ga-68 ABY-025 uptake (SUVmax, 21), who previously received three lines of treatment. F-18 FDG-PET/CT follow-up showed complete metabolic response. (B) Patient with low uptake (SUVmax, 5.4), who previously received three lines of treatment. F-18 FDG PET/CT follow-up showed disease progression (a 68% increase in tumor glycolysis) despite HER2-targeted treatment. (C) Patient with heterogeneous Ga-68 ABY-025 uptake, who previously received seven lines of treatment. F-18 FDG-PET/CT follow-up showed heterogeneous response, with lesions higher in Ga-68 ABY-025 uptake tending to have better response. Arrows indicate biopsy sites. Image courtesy of the Journal of Nuclear Medicine.

PET/MRI superior for diagnosing cardiac sarcoidosis

PET/MRI scans are more accurate for diagnosing cardiac sarcoidosis than established imaging approaches, as well as reduces patient radiation and imaging times.

September 29, 2023

Images in a 52-year-old woman with cardiac sarcoidosis. Standard-of-care imaging (top row) demonstrates a perfusion defect on SPECT images (top left) and corresponding FDG radiotracer uptake on PET/CT image (top right) at the interventricular septum (green arrows). On combined F-18 FDG-PET/MRI (bottom row), there is nodular late gadolinium enhancement (LGE) at the interventricular septum (orange arrows) with corresponding FDG uptake (blue arrows). Image courtesy of Radiology: Cardiothoracic Imaging.

IAEA's Rays of Hope initiative establishes anchor centers

Rays of Hope – the International Atomic Energy Agency's (IAEA) flagship cancer initiative – has named inaugural "anchor centers" in five countries.

September 29, 2023

'Hype' is over for PET/MRI, experts say

PET/MRI has entered the "Slope of Enlightenment" phase of the Gartner Hype Cycle, according to experts.

September 26, 2023

The Gartner Hype Cycle

PET radiomics model identifies high-risk lymphoma patients

A group in the Netherlands has built a radiomics model using FDG-PET scans that predicts disease-free survival odds in patients with relapsed lymphoma.

September 25, 2023

Rare finding detected on PSMA-PET: A nonprostatic lung tumor

A group in Australia has described a rare finding during a prostate cancer restaging PET/CT scan – a pulmonary tumor embolism.

September 25, 2023

Hybrid contrast-enhanced CT (with iodinated contrast bolus timed to maximize pulmonary arterial visualization) and F-18 DCFPyL PSMA-PET images. Contrast CT images (A, B) show an eccentric filling defect in the superior lingula segmental artery of the left lung upper lobe (red arrow). This is concordant with moderately intense PSMA radiotracer expression (black arrows on axial PET-only images, C, and on whole-body maximum intensity projection image, E). Fused PET and contrast-enhanced CT axial image (D) also confirm the lesion (red arrow). No other site of PSMA expressing metastasis is evident on whole-body imaging (E).

Is Pylarify better than Ga-68 PSMA-11 for prostate cancer imaging?

Subtle differences in how PSMA-PET radiotracers perform in patients before Pluvicto treatment may determine which become the future tracers of choice.

September 22, 2023

PSMA-PET imaging

Page 20 of 607